David A. Siegel Protara Therapeutics, Inc. Transaction History
Two Sigma Advisers, LP
- $42.5 Billion
- Q1 2024
A detailed history of David A. Siegel (Two Sigma Advisers, LP) transactions in Protara Therapeutics, Inc. stock. As of the latest transaction made, Two Sigma Advisers, LP holds 27,018 shares of TARA stock, worth $56,737. This represents 0.0% of its overall portfolio holdings.
Number of Shares
27,018
Previous 27,018
-0.0%
Holding current value
$56,737
Previous $50,000
116.0%
% of portfolio
0.0%
Previous 0.0%
Shares
13 transactions
Others Institutions Holding TARA
# of Institutions
40Shares Held
4.55MCall Options Held
102KPut Options Held
18.2K-
Opaleye Management Inc. Boston, MA2.69MShares$5.65 Million2.63% of portfolio
-
Vanguard Group Inc Valley Forge, PA428KShares$897,9850.0% of portfolio
-
Boxer Capital, LLC San Diego, CA209KShares$439,3760.04% of portfolio
-
Ikarian Capital, LLC Dallas, TX203KShares$425,6720.11% of portfolio
-
Baker Bros. Advisors LP New York, NY200KShares$419,3090.01% of portfolio
About Protara Therapeutics, Inc.
- Ticker TARA
- Exchange NASDAQ
- Sector Healthcare
- Industry Biotechnology
- Shares Outstandng 11,267,400
- Market Cap $23.7M
- Description
- Protara Therapeutics, Inc., a clinical-stage biopharmaceutical company, engages in the identifying and advancing transformative therapies for the treatment of cancer and rare diseases. The company's lead program is TARA-002, an investigational cell therapy for the treatment of lymphatic malformations. It also develops intravenous choline chlorid...